FY2024 Earnings Estimate for Actinium Pharmaceuticals, Inc. Issued By Cantor Fitzgerald (NYSEAMERICAN:ATNM)

Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM - Free Report) - Equities researchers at Cantor Fitzgerald increased their FY2024 earnings estimates for Actinium Pharmaceuticals in a research report issued to clients and investors on Tuesday, April 30th. Cantor Fitzgerald analyst K. Kluska now forecasts that the biotechnology company will post earnings of ($1.35) per share for the year, up from their prior forecast of ($1.84). Cantor Fitzgerald currently has a "Overweight" rating and a $21.00 target price on the stock. The consensus estimate for Actinium Pharmaceuticals' current full-year earnings is ($1.76) per share.

A number of other research analysts have also recently weighed in on ATNM. StockNews.com upgraded shares of Actinium Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Monday. HC Wainwright reaffirmed a "buy" rating and issued a $50.00 price objective on shares of Actinium Pharmaceuticals in a research report on Monday. Finally, Maxim Group raised their price target on shares of Actinium Pharmaceuticals from $20.00 to $30.00 and gave the stock a "buy" rating in a research report on Tuesday, March 19th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company's stock. According to MarketBeat.com, Actinium Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average price target of $25.72.

Actinium Pharmaceuticals Stock Up 12.5 %

ATNM stock traded up $0.97 during mid-day trading on Thursday, reaching $8.75. 681,831 shares of the stock traded hands, compared to its average volume of 324,885. Actinium Pharmaceuticals has a one year low of $4.00 and a one year high of $9.86. The stock has a market capitalization of $260.58 million, a price-to-earnings ratio of -4.82 and a beta of 0.08.

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM - Get Free Report) last announced its quarterly earnings results on Friday, March 29th. The biotechnology company reported ($0.33) earnings per share for the quarter, topping the consensus estimate of ($0.54) by $0.21. The business had revenue of $0.08 million during the quarter.

Institutional Investors Weigh In On Actinium Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Creative Financial Designs Inc. ADV raised its holdings in shares of Actinium Pharmaceuticals by 19.1% during the 4th quarter. Creative Financial Designs Inc. ADV now owns 19,800 shares of the biotechnology company's stock worth $101,000 after acquiring an additional 3,175 shares during the period. Sanders Morris Harris LLC purchased a new position in shares of Actinium Pharmaceuticals during the 1st quarter worth $78,000. Finally, Brandywine Global Investment Management LLC purchased a new position in shares of Actinium Pharmaceuticals during the 3rd quarter worth $1,033,000. Institutional investors and hedge funds own 27.50% of the company's stock.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.